We welcome your views on our website and invite you to take part in a brief survey when you've finished your visit.
Your response will help us improve the site and the experience we offer to visitors.
Spire Healthcare, along with all NHS and independent healthcare organisations, recently received further updated guidance from the Medicines and Healthcare products Regulatory Agency (MHRA) regarding patients who received a ‘metal-on-metal’ (MoM) hip replacement system following on from previous guidance released in 2015.
This updates the recommended follow-up arrangements for patients with this type of implant.
The British Orthopaedic Association states: ‘The majority of patients with these devices have well-functioning hips. While a few may develop soft tissue reactions related to their implant, the evidence shows that the best outcomes are achieved if these problems are detected early, monitored and treated if necessary.’
The MHRA has advised that all patients with a MoM hip replacement system – either with a stem or resurfacing - should be offered periodic follow-up appointments depending on the specific type of MoM implant type they received, along with a blood test and in some cases additional imaging. These additional check-ups are a precautionary measure so that any potential issues with their implant can be identified and addressed at an early stage.
As a result, we have written to patients who received a MoM system at a Spire hospital to advise them of the MHRA guidance and to ensure they are being followed up in line with their recommendations.
If any Spire patient is concerned or has questions in relation to this matter, please contact our dedicated helpline in the first instance (0800 085 8996) and we will endeavour to answer any questions you may have. The helpline is open between 08:30am and 8:00pm Monday to Friday, and 09.00am and 5.00pm on Saturdays.